Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-10-29
2009-12-29
Saeed, Kamal A (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S399000, C514S254050, C548S335500, C548S338100, C548S469000, C544S370000
Reexamination Certificate
active
07638546
ABSTRACT:
The present invention is directed to imidazolyl derivatives of formula (I) where the substituents are defined in the specification, which are useful as agonist or antagonists of somatostatin receptors.
REFERENCES:
patent: 5128355 (1992-07-01), Carini et al.
patent: 5733882 (1998-03-01), Carr et al.
patent: 6852725 (2005-02-01), Thurieau et al.
patent: 7238695 (2007-07-01), Thurieau et al.
patent: 0 166 609 (1986-01-01), None
patent: 2 132 632 (1972-11-01), None
patent: 218 460 (1987-09-01), None
patent: 01-203383 (1989-08-01), None
patent: 94/04494 (1994-03-01), None
patent: 95/08550 (1995-03-01), None
patent: 96/00730 (1996-01-01), None
patent: 96/11927 (1996-04-01), None
patent: 96/16040 (1996-05-01), None
patent: 97/24119 (1997-07-01), None
patent: 97/30053 (1997-08-01), None
patent: 97/43278 (1997-11-01), None
patent: 97/45425 (1997-12-01), None
patent: 98/27108 (1998-06-01), None
patent: 99/64401 (1999-12-01), None
patent: 99/65942 (1999-12-01), None
patent: WO 9964401 (1999-12-01), None
patent: 00/00477 (2000-01-01), None
Albert, Rainer, et al.; “Direct Synthesis of [DOTA-Dphe1]-Octreotide (SMT487): . . . ”; Bioorganic & Medicinal Chemistry Letters, 1998,vol. 8; pp. 1207-1210; XP002124712.
Al-Dabbagh et al., “Species differences in oxidative drug metabolism: some basic considerations,” Archives of Toxicology, 1984Supplement 7:219-231.
Avallone, L. et al., “Research on heterocyclic compounds, XXXV[1]. Synthesis of 2-phenylimidazo[1,2-a]-pyrazine-3-acetates”, Monatshefte fur Chemie, 1996, 127:947-953.
Barraclough, P. et al., “Synthesis and pharmacological properties of BW315C and other inotropic 2-arylimidazo[1,2-a]pyrazines”, Bioroganic & Med. Chem. Letters, 1993, 3:509-514.
Bornowski, Heinz et al.; Chem. Abstract 1973, 78:13689.
Bundgaard, Hans, Design of Prodrugs, 1985, p. 1, Elsevier Science Publishers.
Ellinger and Goldberg; J. Chem. Soc.; 1949; 263, 266; Beilstein Registry No. 1965.
Ellinger and Goldberg; J. Chem. Soc.; 1949; 263, 266; Beilstein Registry No. 3689018.
Ellinger and Goldberg; J. Chem. Soc.; 1949; 263, 266; Beilstein Registry No. 3798855.
Emery, P.T.J. et al., “Anti-secretory properties of non-peptide somatostatin receptor agonists in isolated rat colon: luminal activity and possible interaction with p-glycoprotein,” Br. J. Pharm., 135:1443-1448, 2002.
Gordon, T. D. et al., “Synthetic approaches to the “azole” peptide mimetics,” Tet. Lett., 34:1901-1904, 1993.
Gordon, Thomas D. et al.; Chem. Abstract 1997, 127:248417.
Gramberg, Dieter et al; “Synthesis of a Type Vibeta-Turn Peptide . . . ”;Helvetica Chimica Acta; 1995, vol. 78, pp. 1588-1606; XP000612160.
Hirschmann, Ralph et al.; “De Novo Design and Synthesis of Somatostatin . . . ”; Journal of the American Chemical Society; 1996, vol. 115, No. 26; pp. 12550-12568; XP002124710.
Hirschmann, Ralph et al.; “Nonpeptidal Peptidomimetics with a beta-D-glucose Scaffolding”; Journal of the American Chemical Society; 1992, vol. 114, No. 23; XP002124711.
Miller, William H. et al.; Chem. Abstract 1997, 127:161822.
Morgenstern, R. et al., “Antihistamine activity of some 4-phenylimidazoles”, Pharmazie, 1975, 30:103-105. (in English).
Papageorgiou, Christos et al.; “A Non-peptide ligand for the Somatostatin Receptor having a Benzodiazepinone Structure”; Bioorganic & Medicinal Chemistry Letters; 1996, vol. 6, No. 3; pp. 267-272; XP004135075.
Silverman, R., The Organic Chemistry of Drug Design and Drug Action, 1992, p. 352-400, Academic Press, Inc.
Spitzer, W. A. et al., “Imidazo[1,2-1]pyrimidines and imidazo[1,2-a]pyrazines: the role of nitrogen position in inotropic activity”, J. Med. Chem., 1988, 31:1590-1595.
Stocker, Fred B. et al.; Chem. Abstract, 1970, 72:121434.
Towliati, Hossein; Chem. Abstract, 1971, 74:53642.
Towliati, H. “Report on the synthesis of imidazole derivatives”, Chem. Reports., 1970, 103:3952-3953. (English translation).
Von Geldern, Thomas W. et al.; Chem Abstract, 1996, 124:193276.
Von Geldern, Thomas W. et al.; Chem. Abstract, 1996, 124:127005.
Von Geldern, Thomas W. et al.; Chem. Abstract, 1996, 124:164291.
Von Geldern et al., “Azole endothelin antagonists. 1. A receptor model explains an unusual structure-activity profile,” J. Med. Chem., 1996, 394(4):957-967.
Werbel, L. M. et al., “Synthesis of fused imidazo-heterocyclic systems”, J. Heterocyclic Chem., 1965, 2:287-290.
Bigg Dennis C. H.
Galcera Marie-Odile
Gordon Thomas D.
Moinet Christophe Philippe
Morgan Barry A.
Feeney Alan F.
Fish & Richardson
IPSEN Pharma S.A.S.
Rodriguez-Garcia Valerie
Saeed Kamal A
LandOfFree
Imidazolyl derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Imidazolyl derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Imidazolyl derivatives will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4108135